rss
Evid Based Nurs 8:78 doi:10.1136/ebn.8.3.78
  • Treatment

Maintenance and symptom relief with budesonide plus formoterol reduced severe asthma exacerbations


 
 Q In patients with asthma, is budesonide (BUD) plus formoterol (FORM) (BUDFORM) for both maintenance and symptom relief more effective than fixed dosing using BUDFORM or a 4 fold higher dose of BUD, both with a short acting β2 agonist (SABA), for reducing the rate of severe asthma exacerbations?

METHODS

GraphicDesign:

randomised controlled trial.

GraphicAllocation:

concealed.

GraphicBlinding:

blinded (patients and healthcare providers).

GraphicFollow up period:

1 year

GraphicSetting:

246 centres in 22 countries.

GraphicPatients:

2760 outpatients (mean age 36 y, 55% women/girls; 12% children 4–11 y) with asthma who were using inhaled corticosteroids (ICSs).

GraphicIntervention:

BUDFORM (BUD, 80 μg plus FORM, 4.5 μg) both for maintenance and as needed (BUDFORM for all, n = 925); BUDFORM for maintenance plus terbutaline, 0.4 mg as needed (BUDFORM plus SABA, n = 909); or BUD, 320 …

No Related Web Pages

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>

EBN Journal Chat

The EBN Journal Chat offers readers the opportunity to participate in discussion about research articles and commentaries from Evidence Based Nursing (EBN).

How to participate >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article